Tuberculosis Clinical Trials

151 recruitingLast updated: June 17, 2026

There are 151 actively recruiting tuberculosis clinical trials across 61 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4. Top locations include Kampala, Uganda, Cape Town, South Africa, Cape Town, Western Cape, South Africa. Updated daily from ClinicalTrials.gov.


Tuberculosis Trials at a Glance

151 actively recruiting trials for tuberculosis are listed on ClinicalTrialsFinder across 6 cities in 61 countries. The largest study group is Not Applicable with 38 trials, with the heaviest enrollment activity in Kampala, Cape Town, and Cape Town. Lead sponsors running tuberculosis studies include Johns Hopkins University, University of California, San Francisco, and Huashan Hospital.

Browse tuberculosis trials by phase

Treatments under study

About Tuberculosis Clinical Trials

Looking for clinical trials for Tuberculosis? There are currently 81 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Tuberculosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Tuberculosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 151 trials

Recruiting

Prospective Cohort of People Starting Treatment for Tuberculosis Disease in France (FrenchTB)

Tuberculosis
ANRS, Emerging Infectious Diseases2,000 enrolled2 locationsNCT06893757
Recruiting
Phase 3

Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis

Acute Coronary SyndromeTuberculosisPulmonary Hypertension (Diagnosis)
National University Hospital, Singapore150 enrolled6 locationsNCT05473520
Recruiting
Phase 2

Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB

Tuberculosis, Multidrug-Resistant
Janssen Research & Development, LLC60 enrolled11 locationsNCT02354014
Recruiting

Training Protocol on the Natural History of Tuberculosis

TuberculosisLatent TuberculosisMycobacterium Infections+2 more
National Institute of Allergy and Infectious Diseases (NIAID)150 enrolled1 locationNCT01212003
Recruiting

Effect of Mycobacterial Infection on Immune Status

Tuberculosis
First Affiliated Hospital of Ningbo University120 enrolled1 locationNCT07638670
Recruiting
Phase 2Phase 3

Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB

Tuberculosis, Latent
Johns Hopkins University2,530 enrolled6 locationsNCT06568484
Recruiting
Phase 2

Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis

Drug Susceptible Pulmonary Tuberculosis
Gates Medical Research Institute150 enrolled13 locationsNCT07525427
Recruiting
Phase 2

Adjunctive Doxycycline for Central Nervous System Tuberculosis

Tuberculosis, MeningealTuberculosis; Meningitis (Etiology)Tuberculosis, Central Nervous System+1 more
National University Hospital, Singapore200 enrolled6 locationsNCT06446245
Recruiting
Phase 3

Shortened Regimen for Drug-susceptible TB in Children

TuberculosisTuberculosis, PulmonaryMycobacterium Tuberculosis+1 more
Johns Hopkins University860 enrolled9 locationsNCT06253715
Recruiting
Not Applicable

Clinic-based Versus Hotspot-focused Active TB Case Finding

Tuberculosis, PulmonaryMycobacterium Tuberculosis Infection
Johns Hopkins University150,000 enrolled1 locationNCT05285202
Recruiting
Not Applicable

An Adaptive Randomized Controlled Trial

HIV InfectionsMulti Drug Resistant Tuberculosis
Columbia University360 enrolled1 locationNCT05633056
Recruiting
Phase 2

Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis

Drug Susceptible Pulmonary Tuberculosis
Gates Medical Research Institute165 enrolled4 locationsNCT07517445
Recruiting
Phase 2

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Pulmonary Tuberculosis
National Institute of Allergy and Infectious Diseases (NIAID)315 enrolled29 locationsNCT06192160
Recruiting
Phase 4

Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment

Therapeutic Drug Monitoring (TDM)LinezolidTuberculosis Multi Drug Resistant Active
Marco Schiuma150 enrolled1 locationNCT07477119
Recruiting

TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung Disease

Lung DiseaseFunctional CapacitySpirometry+1 more
Universitas Padjadjaran20 enrolled1 locationNCT07451899
Recruiting
Phase 2Phase 3

Shorter and Safer Treatment Regimens for Latent TB

Tuberculosis Infection, Latent
McGill University Health Centre/Research Institute of the McGill University Health Centre1,800 enrolled14 locationsNCT06498414
Recruiting
Phase 3

A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

Pulmonary Tuberculosis
Otsuka Pharmaceutical Development & Commercialization, Inc.532 enrolled35 locationsNCT07209761
Recruiting
Phase 2Phase 3

Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

Latent Tuberculosis
Centers for Disease Control and Prevention3,400 enrolled21 locationsNCT03474029
Recruiting
Not Applicable

Rapid Research in Diagnostics Development for TB Network

Tuberculosis
University of California, San Francisco26,436 enrolled16 locationsNCT04923958
Recruiting

A 15-year Cohort Study on Risk Factors of Mortality in Patients With Intestinal Tuberculosis

Intestinal Tuberculosis
Beijing Chest Hospital, Capital Medical University500 enrolled1 locationNCT07575061